2[2]Lan K,Zucker D.Sequential monitoring of clinical trails:the role of information and Brownian motion[J].Statistic Med,1993;12:753-765
二级参考文献2
1Center for Drug Evaluation,Food and Drug Administration.Guideline for the format and content of the clinical and statistical sections of an application[J/OL].http://www.fda.gov/cder/guidance/statnda.pdf,1988 -06 -05.
6Glasser S P, Salas M, DeIzell E. Importance and challenges of studying marketed drugs: What is a phase IV study? Common clinical research designs, registries, and self-reporting systems [J]. J Clin Pharmacol, 2007,47(9) :1074.
7Farahani P, Levine M, Gaebel K, Thabane L. Clinical data gap between phase Ill clinical trials (pre-marketing) and phase IV (post-marketing) studies: Evaluation of etanercept in rheumatoid arthritis[J]. Can J Clin Pharmacol, 2005,12(3) :e254.
8Vijan S, Kent D M, Hayward R A. Are randomized controlled tri- Ms sufficient evidence to guide clinical practice in type II (noninsulin-dependent) diabetes mellitus? [ J ]. Diabetologia, 2000, 43(1 ) :125.
9Hayward R A, Kent D M, Vijan S, et al. Reporting clinical trial results to inform providers, payers, and consumers [ J ]. Health Aft (Millwood) ,2005,24 ( 6 ) : 1571.
